Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gerilimzumab
- Development stage
- Phase 2
- Lead developer
- argenx
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Gerilimzumab is a recombinant humanized IgG1λ monoclonal antibody that targets and neutralizes interleukin-6 (IL-6), a pro-inflammatory cytokine implicated in autoimmune diseases and cancer. Developed using the SIMPLE Antibody™ platform by argenx and further enhanced with NHance® technology to prolong circulation time and improve tissue distribution, gerilimzumab was designed for low-frequency subcutaneous dosing. It has demonstrated favorable safety, pharmacokinetics (long half-life), low immunogenicity in healthy volunteers, and dose-dependent increases in serum IL-6 levels. The drug was developed collaboratively by argenx, Bird Rock Bio (formerly RuiYi), and Genor Biopharma for indications including rheumatoid arthritis, autoimmune disorders, inflammation-related conditions, and certain cancers[1][4][5][7].
- Other names
- gerilimzumab
02
Targets
IL-6 (Interleukin 6)
Beyond the preview
Go deeper on gerilimzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gerilimzumab.